Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis

Bozho Todorich, Glenn C Yiu, Paul Hahn

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Retinal vascular development is a carefully orchestrated developmental process during which retinal and choroidal vasculature form to provide a dual vascular supply to the neurosensory retina and retinal pigment epithelium. The most common causes of vision loss in children and adults involve at least in part perturbation of the normal vascular physiology or development. Vascular endothelial growth factor has emerged as a key molecular regulator of retinal vascular development as well as retinal and choroidal neovascularization, which underlie the pathophysiology of many retinal diseases. Over the past decade, the advent of injectable pharmacotherapeutic agents into the vitreous cavity of the eye has revolutionized our management of neovascular age-related macular degeneration and other retinal diseases and has, for the first time, offered an opportunity to improve vision rather than just slow the progression of disease processes. The transient duration of these agents, however, requires chronic treatment with repeated intraocular injections and significant treatment burden for patients and the healthcare system. Novel treatments modulating retinal angiogenesis offer the promise of improved efficacy, decreased treatment burden and improved cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)375-391
Number of pages17
JournalExpert Review of Clinical Pharmacology
Volume7
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Retinal Diseases
Retinal Vessels
Blood Vessels
Intraocular Injections
Retinal Neovascularization
Choroidal Neovascularization
Retinal Pigment Epithelium
Macular Degeneration
Vascular Endothelial Growth Factor A
Cost-Benefit Analysis
Disease Progression
Retina
Therapeutics
Delivery of Health Care
Injections

Keywords

  • Aflibercept
  • Age-related macular degeneration
  • Bevacizumab
  • Choroidal neovascularization
  • Diabetic retinopathy
  • Ranizbizumab
  • Retinal neovascularization

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Medicine(all)

Cite this

Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. / Todorich, Bozho; Yiu, Glenn C; Hahn, Paul.

In: Expert Review of Clinical Pharmacology, Vol. 7, No. 3, 2014, p. 375-391.

Research output: Contribution to journalReview article

@article{c5dda48678d04de08822593157d8a3f4,
title = "Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis",
abstract = "Retinal vascular development is a carefully orchestrated developmental process during which retinal and choroidal vasculature form to provide a dual vascular supply to the neurosensory retina and retinal pigment epithelium. The most common causes of vision loss in children and adults involve at least in part perturbation of the normal vascular physiology or development. Vascular endothelial growth factor has emerged as a key molecular regulator of retinal vascular development as well as retinal and choroidal neovascularization, which underlie the pathophysiology of many retinal diseases. Over the past decade, the advent of injectable pharmacotherapeutic agents into the vitreous cavity of the eye has revolutionized our management of neovascular age-related macular degeneration and other retinal diseases and has, for the first time, offered an opportunity to improve vision rather than just slow the progression of disease processes. The transient duration of these agents, however, requires chronic treatment with repeated intraocular injections and significant treatment burden for patients and the healthcare system. Novel treatments modulating retinal angiogenesis offer the promise of improved efficacy, decreased treatment burden and improved cost-effectiveness.",
keywords = "Aflibercept, Age-related macular degeneration, Bevacizumab, Choroidal neovascularization, Diabetic retinopathy, Ranizbizumab, Retinal neovascularization",
author = "Bozho Todorich and Yiu, {Glenn C} and Paul Hahn",
year = "2014",
doi = "10.1586/17512433.2014.890047",
language = "English (US)",
volume = "7",
pages = "375--391",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis

AU - Todorich, Bozho

AU - Yiu, Glenn C

AU - Hahn, Paul

PY - 2014

Y1 - 2014

N2 - Retinal vascular development is a carefully orchestrated developmental process during which retinal and choroidal vasculature form to provide a dual vascular supply to the neurosensory retina and retinal pigment epithelium. The most common causes of vision loss in children and adults involve at least in part perturbation of the normal vascular physiology or development. Vascular endothelial growth factor has emerged as a key molecular regulator of retinal vascular development as well as retinal and choroidal neovascularization, which underlie the pathophysiology of many retinal diseases. Over the past decade, the advent of injectable pharmacotherapeutic agents into the vitreous cavity of the eye has revolutionized our management of neovascular age-related macular degeneration and other retinal diseases and has, for the first time, offered an opportunity to improve vision rather than just slow the progression of disease processes. The transient duration of these agents, however, requires chronic treatment with repeated intraocular injections and significant treatment burden for patients and the healthcare system. Novel treatments modulating retinal angiogenesis offer the promise of improved efficacy, decreased treatment burden and improved cost-effectiveness.

AB - Retinal vascular development is a carefully orchestrated developmental process during which retinal and choroidal vasculature form to provide a dual vascular supply to the neurosensory retina and retinal pigment epithelium. The most common causes of vision loss in children and adults involve at least in part perturbation of the normal vascular physiology or development. Vascular endothelial growth factor has emerged as a key molecular regulator of retinal vascular development as well as retinal and choroidal neovascularization, which underlie the pathophysiology of many retinal diseases. Over the past decade, the advent of injectable pharmacotherapeutic agents into the vitreous cavity of the eye has revolutionized our management of neovascular age-related macular degeneration and other retinal diseases and has, for the first time, offered an opportunity to improve vision rather than just slow the progression of disease processes. The transient duration of these agents, however, requires chronic treatment with repeated intraocular injections and significant treatment burden for patients and the healthcare system. Novel treatments modulating retinal angiogenesis offer the promise of improved efficacy, decreased treatment burden and improved cost-effectiveness.

KW - Aflibercept

KW - Age-related macular degeneration

KW - Bevacizumab

KW - Choroidal neovascularization

KW - Diabetic retinopathy

KW - Ranizbizumab

KW - Retinal neovascularization

UR - http://www.scopus.com/inward/record.url?scp=84898907867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898907867&partnerID=8YFLogxK

U2 - 10.1586/17512433.2014.890047

DO - 10.1586/17512433.2014.890047

M3 - Review article

VL - 7

SP - 375

EP - 391

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -